Abstract
Augmenting sertraline with eicosapentaenoic acid (EPA) for 10 weeks did not improve depressive symptoms relative to placebo in a group of 144 patients with major depressive disorder and existing or high risk of heart disease, a randomized trial has found. These results were inconsistent with findings of previous research showing that EPA supplementation improved the efficacy of standard antidepressant treatment.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call